Jianliang Xu

Dr. Jianliang Xu is an Assistant Professor of Biology at Georgia State University. He holds a Ph.D. in Biochemistry and Molecular Biology from Nanjing University, with postdoctoral training at Kyoto University under Nobel Laureate Tasuku Honjo and at the National Institutes of Health. His research focuses on developing nanobody-based technologies against viral pathogens including SARS-CoV-2, HIV-1, and emerging viruses.

Research objectives include establishing efficient nanobody development platforms, creating transgenic nanobody-producing mouse models (Nanomice), and generating therapeutic nanobodies against high-priority viruses. Current projects target conserved viral epitopes using single-domain antibody engineering for broad-spectrum neutralization.

Publications demonstrate breakthroughs in nanobody development against SARS-CoV-2 variants, bispecific antibody engineering against HIV-1, and fundamental studies of antibody diversification mechanisms. His NIH research contributed to COVID-19 therapeutic development during the pandemic.